Abstract
ABSTRACT
Dry powder inhaler (DPI) delivery systems provide advantages over the metered-dose inhaler (MDI) systems. Of the anti-asthma agents studied, most of the trials have focused on the beta adrenergic agonists with a lesser degree of inhaled cromoglycate and corticosteroids. The results of the studies show either similarities or a lesser effect on pulmonary function for the DPI systems but, in most cases, clinical symptoms are comparable. The trials reported vary in the type of controlled designs, doses, and systems evaluated, hence scrutiny of resultant data should follow assessment of methodology in order to clinically interchange these systems in asthmatic patients.
Get full access to this article
View all access options for this article.